Helix Announces Multi-Year Agreement with Alnylam to Drive Precision Medicine Development

Partnership provides Alnylam access to Helix's GenoSphere cohorts to accelerate RNAi therapeutics research

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Helix, the leading enterprise genomics company, announced a multi-year relationship with Alnylam, the leading RNAi therapeutics company. This agreement provides Alnylam access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas, which Alnylam will use to identify new targets for its innovative RNAi therapeutics.

Why it matters

This partnership highlights the growing importance of genomic data and precision medicine in drug discovery and development. By leveraging Helix's extensive genomic and clinical datasets, Alnylam aims to accelerate its efforts to develop new RNAi-based treatments that target the underlying genetic drivers of disease.

The details

Under the multi-year agreement, Alnylam will gain access to Helix's GenoSphere™ cohorts, which consist of comprehensive Exome+® genomic data and rich longitudinal clinical information from a diverse patient population across North America. Alnylam plans to use this data to guide its drug discovery efforts and identify new targets for its RNAi therapeutics, an innovative class of medicines that silence genes that cause or contribute to disease.

  • Helix and Alnylam announced the multi-year agreement on March 5, 2026.

The players

Helix

The leading enterprise genomics company that transforms health systems and enables life science organizations to leverage the power of genomics.

Alnylam Pharmaceuticals

The leading RNAi therapeutics company that uses human genetics to guide its drug discovery efforts.

Paul Nioi

SVP of Research at Alnylam Pharmaceuticals.

James Lu

CEO of Helix.

Got photos? Submit your photos here. ›

What they’re saying

“We believe that access to the Helix platform will bolster our efforts to identify new targets for RNAi therapeutics, an innovative class of medicines that silence genes that cause or contribute to disease.”

— Paul Nioi, SVP, Research at Alnylam Pharmaceuticals (PRNewswire)

“We are excited to establish this relationship with Alnylam. It further validates the unparalleled scale and depth of our platform and exemplifies Helix as a global catalyst in helping transform precision medicine development across major therapeutic areas to improve patient outcomes and lives.”

— James Lu, CEO of Helix (PRNewswire)

What’s next

Helix and Alnylam plan to continue collaborating to leverage Helix's genomic and clinical datasets to accelerate Alnylam's RNAi therapeutics research and development.

The takeaway

This partnership demonstrates the growing importance of genomic data and precision medicine in the drug discovery and development process. By combining Helix's extensive datasets with Alnylam's expertise in RNAi therapeutics, the companies aim to identify new targets and develop innovative treatments that can improve patient outcomes.